SoVarGen
- Company typePrivate
- Founded2018
- HeadquartersDaejeon, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SoVarGen does
SoVarGen is a South Korean clinical-stage biotechnology company developing RNA-based therapeutics, principally antisense oligonucleotides (ASOs), for intractable neurological disorders caused by brain somatic mosaicism. Founded in 2018 by KAIST Professor Jeong Ho Lee and headquartered at the KAIST Munji Campus in Daejeon with a Seoul business development office, the company targets drug-resistant epilepsies (Focal Cortical Dysplasia Type II and Tuberous Sclerosis Complex epilepsy), pediatric brain tumors (BRAF-mutant low-grade glioma), and glioblastoma. The lead clinical-stage asset is SVG103 (paxalisib, an oral PI3K/mTOR inhibitor) in trials in Australia and Korea; SVG105 (ASO for FCD II epilepsy) is in IND-enabling studies; and SVG301 (ASO for BRAF-mutant LGG) and SVG104 (gene therapy for MOGHE) are in earlier research.
The company operates an integrated proprietary discovery platform called Sovarna, comprising three core technologies: Sovarin (ultra-low-frequency somatic mutation detection via the RePlow pipeline at VAF<1%), Sovarup (brain disease-specific translational models that introduce disease-causing somatic mutations into the same human cell types), and Sovaron (ASO drug discovery combining AI-driven sequence screening, high-throughput screening, neurotoxicity assessment, and translational efficacy validation). The platform is supported by a biorepository of over 3,000 patient brain tissue samples and 50+ peer-reviewed publications.
SoVarGen is pre-commercial and generates revenue through technology out-licensing and co-development partnerships with global pharmaceutical companies, supplemented by Korean government grants (e.g., KDDF). Revenue is realized as upfront payments, development and regulatory milestones, and royalties on commercialized products. The company's lead commercial milestone is a January 2026 technology transfer agreement with Angelini Pharma for the intractable epilepsy ASO candidate, valued at approximately 770 billion KRW (~$550M USD headline value), one of the largest Korean biotech licensing transactions. The company is preparing for a KOSDAQ IPO with NH Investment & Securities as lead underwriter.
SoVarGen firmographics
Firmographics- Name
- SoVarGen
- Legal name
- 소바젠 주식회사 (Sovargen Co., Ltd.)
- Website
- https://sovargen.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SoVarGen industry classification
Industry- Product category
- RNA Therapeutics / CNS Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)
- akta.pro secondary industries
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)
Keywords
Where SoVarGen is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
SoVarGen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology Licensing / Out-licensing: The company generates revenue through licensing its proprietary ASO candidates and platform technology to global pharmaceutical partners. Revenue is realized through upfront payments, milestone payments tied to development, regulatory, and commercial achievements, and potential royalties on product sales.
- Co-development Partnerships: Collaborative development agreements with pharmaceutical partners where development costs are shared, and the company contributes its proprietary platform and pipeline assets in exchange for development funding and future royalties.
- Research Grants: Government and institutional grants supporting early-stage research and platform development, including KDDF and other Korean government funding programs.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
SoVarGen product offering
Product offeringCore offering
SoVarGen develops antisense oligonucleotide (ASO) RNA therapeutics and a proprietary drug discovery platform (Sovarna®) targeting intractable neurological disorders caused by brain somatic mutations. The company integrates ultra-low frequency mutation detection, disease-specific translational models, and AI-driven ASO design to deliver first-in-class drug candidates for focal epilepsy, brain tumors, and neurodegenerative diseases. Revenue is generated primarily through out-licensing of platform technology and pipeline assets to global pharmaceutical partners.
Product overview
SoVarGen is a biotechnology company developing RNA therapeutics for neurological disorders caused by brain somatic mosaicism. The company operates its proprietary Sovarna platform, which integrates three core technologies: Sovarin (ultra-low frequency mutation detection), Sovarup (brain disease-specific translational research models), and Sovaron (AI-powered ASO drug discovery). The product portfolio includes multiple pipeline candidates: SVG103 (paxalisib, a PI3K/mTOR inhibitor in clinical trials for TSC epilepsy), SVG105 (ASO for FCD II epilepsy in IND-enabling studies), SVG301 (ASO for BRAF-mutant LGG), and SVG104 (gene therapy for MOGHE). The platform enables first-in-class drug development targeting the root genetic drivers of intractable brain diseases through precision ASO medicines.
Differentiator
Problem solved
Functional benefit
Brands
- Sovarna: Proprietary ASO drug discovery platform for intractable brain diseases caused by somatic mutations, comprising three core technologies: Sovarin (mutation detection), Sovarup (translational research models), and Sovaron (ASO drug discovery).
- Sovarin
- Sovarup
- Sovaron
Products and services
- Sovarna® Platform
Quantifiable outcome
- Technology transfer deal valued at 7,500-7,800 billion KRW with Angelini Pharma for epilepsy ASO treatment.
- +1 more outcomes
Companies that use SoVarGen
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
SoVarGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
SoVarGen partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, core and minor.
- Angelini PharmaflagshipMajor technology licensing agreement for SoVarGen's ASO-based intractable epilepsy treatment. Described as a 7,500-7,800 billion KRW deal (approximately $5.5-5.8 billion USD), representing one of the largest biotech licensing deals from Korea. Angelini Pharma is a global pharmaceutical company focused on Brain Health, operating across 21 countries with €1.6 billion in revenue.
- 지엘팜텍 (Gyeong Dong Pharmaceutical Tech)coreCo-development partner for SDF01 formulation development. SDF01 is a pediatric intractable epilepsy (Focal Cortical Dysplasia) drug candidate repurposed from an existing marketed drug, with Phase 2 investigator-initiated trial in progress.
- Kazia TherapeuticsminorPartner for SVG103 (paxalisib) clinical development. SVG103 is an oral small-molecule PI3K/mTOR inhibitor for TSC2-associated epilepsy treatment. Clinical trials ongoing in Australia and Korea.
- MOTIR TherapeuticsminorPartner for SVG304 (ASO for GBM) development program targeting glioblastoma with ASO therapy approach.
- World-Renowned Hospitals and Brain BankscoreStrategic collaborations with world-renowned hospitals, research institutes, and brain banks enabling access to over 3,000 patient brain tissue samples integrated with comprehensive clinical records. Essential for Sovarin mutation detection technology validation.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
SoVarGen competitors and assessment
Company assessmentDirect peers
- Stoke Therapeutics: Stoke Therapeutics is the most direct comparable: an ASO-focused biotech targeting CNS diseases caused by genetic mutations, with a lead program (STK-001) for Dravet syndrome and expansion into autosomal dominant optic atrophy. Both companies use ASOs to address root genetic causes of intractable neurological diseases, with similar scientific premise and delivery approaches.
- Ionis Pharmaceuticals: Ionis is the pioneer and commercial leader in antisense oligonucleotide technology, with multiple approved ASO drugs (Spinraza, Tegsedi, Waylivra) and a broad CNS pipeline. SoVarGen's Sovaron ASO discovery platform directly competes with Ionis's chemistry and design capabilities, and Ionis serves as the benchmark for ASO platform valuations.
- Wave Life Sciences: Wave Life Sciences develops stereopure oligonucleotide therapeutics (ASO and siRNA) with a focus on neurological diseases including Huntington's disease and ALS. Comparable to SoVarGen in modality (ASO) and CNS focus, with similar platform-plus-pipeline business model.
Broad incumbents
- Biogen: Biogen commercializes Spinraza (nusinersen), the leading intrathecal ASO for SMA, and has a broad neurology portfolio. As the established commercial leader in CNS ASOs, Biogen represents both a potential acquirer/partner for SoVarGen and a benchmark for commercial scalability of intrathecal ASO therapies.
- Alnylam Pharmaceuticals: Alnylam is the leading siRNA (RNA interference) therapeutics company with multiple approved products and a CNS pipeline. While siRNA is a related but distinct RNA therapeutic modality, Alnylam serves as a key comparable for RNA therapeutics platform valuations and pipeline economics.
- BridgeBio Pharma: BridgeBio develops therapeutics for genetic diseases including CNS indications (e.g., CALR-mutant myelofibrosis, transthyretin amyloidosis with CNS involvement). Comparable in rare disease focus and genetic target validation approach.
Emerging players
- PepGen: PepGen develops conjugated oligonucleotides for neuromuscular and CNS diseases with enhanced cellular uptake. It represents an emerging player in CNS-targeted oligonucleotide therapeutics, addressing similar delivery challenges to SoVarGen's intrathecal approach.
- Marinus Pharmaceuticals: Marinus Pharmaceuticals develops CNS therapeutics for rare seizure disorders (CDKL5 deficiency disorder, tuberous sclerosis complex) with ganaxolone. Directly comparable to SoVarGen's TSC epilepsy focus (SVG103) and broader refractory epilepsy pipeline.
Regional players
- SK Biopharmaceuticals: SK Biopharmaceuticals is a Korean pharmaceutical company focused on CNS therapeutics, with FDA-approved Xcopri for epilepsy and an active licensing/out-licensing business model. Most relevant Korean regional peer for SoVarGen's neurology focus and licensing-led GTM.
- Hanmi Pharmaceutical: Hanmi Pharmaceutical is a major Korean pharma with neurological and rare disease pipelines and significant licensing deal experience. Comparable as a regional Korean peer with platform-based drug discovery and partnership-driven commercialization.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
SoVarGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
SoVarGen leadership team
Management profileNumber of profiles
Profiles7 records
SoVarGen funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SoVarGen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SoVarGen
What does SoVarGen do?
SoVarGen develops antisense oligonucleotide (ASO) RNA therapeutics and a proprietary drug discovery platform (Sovarna®) targeting intractable neurological disorders caused by brain somatic mutations. The company integrates ultra-low frequency mutation detection, disease-specific translational models, and AI-driven ASO design to deliver first-in-class drug candidates for focal epilepsy, brain tumors, and neurodegenerative diseases. Revenue is generated primarily through out-licensing of platform technology and pipeline assets to global pharmaceutical partners.
Is SoVarGen a public or private company?
SoVarGen is a private company. It is classified as venture growth investor backed and is currently operating.
When was SoVarGen founded?
SoVarGen was founded in 2018. It employs 11 to 50 people.
Where is SoVarGen based?
SoVarGen is headquartered in Daejeon, South Korea, in the Asia region.
How does SoVarGen make money?
Three revenue lines are on record. Technology Licensing / Out-licensing is the primary driver. The others are co-development Partnerships and research Grants.
Who are SoVarGen's main competitors?
Direct peers on record are Stoke Therapeutics, Ionis Pharmaceuticals and Wave Life Sciences. Broad incumbents are Biogen, Alnylam Pharmaceuticals and BridgeBio Pharma. Emerging players are PepGen and Marinus Pharmaceuticals. Regional players are SK Biopharmaceuticals and Hanmi Pharmaceutical.
Does SoVarGen have an API?
No public API is recorded for SoVarGen.
What industry is SoVarGen in?
SoVarGen's product category is RNA Therapeutics / CNS Drug Discovery. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.